These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 38655246)
1. National safety monitoring of vaccines from the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS), 2018-2019. El Jaouhari M; Johnson K; Anyoti H; Xu Y; Wells C; Weeks A; Yeung A; Shaw A; Ogunnaike-Cooke S Can Commun Dis Rep; 2024 Jan; 50(1-2):49-57. PubMed ID: 38655246 [TBL] [Abstract][Full Text] [Related]
2. Vaccine safety surveillance in Canada: Reports to CAEFISS, 2017. Johnson K; Anyoti H; Coulby C Can Commun Dis Rep; 2018 Dec; 44(12):324-330. PubMed ID: 31517950 [TBL] [Abstract][Full Text] [Related]
3. Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013-2016. Ahmadipour N; Watkins K; Fréchette M; Coulby C; Anyoti H; Johnson K Can Commun Dis Rep; 2018 Sep; 44(9):206-214. PubMed ID: 31015811 [TBL] [Abstract][Full Text] [Related]
4. Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022. Giang E; Xu Y; Naganathan T; Abraham N; Bawolak MT; Salim BS; Weeks A; Shaw A; Ogunnaike-Cooke S Can Commun Dis Rep; 2024 Jan; 50(1-2):16-24. PubMed ID: 38655243 [TBL] [Abstract][Full Text] [Related]
5. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012. Law BJ; Laflèche J; Ahmadipour N; Anyoti H Can Commun Dis Rep; 2014 Dec; 40(Suppl 3):7-23. PubMed ID: 29769908 [TBL] [Abstract][Full Text] [Related]
6. Adverse events following immunization in Ontario's female school-based HPV program. Harris T; Williams DM; Fediurek J; Scott T; Deeks SL Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208 [TBL] [Abstract][Full Text] [Related]
7. Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada. Top KA; Constantinescu CM; Laflèche J; Bettinger JA; Scheifele DW; Vaudry W; Halperin SA; Law BJ Vaccine; 2013 Nov; 31(48):5700-5. PubMed ID: 24099871 [TBL] [Abstract][Full Text] [Related]
8. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015. Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723 [TBL] [Abstract][Full Text] [Related]
9. Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health. Inokuma Y; Kneller R Eur J Clin Pharmacol; 2023 Jul; 79(7):989-1002. PubMed ID: 37249640 [TBL] [Abstract][Full Text] [Related]
10. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study. Sebastian J; Gurumurthy P; Ravi MD; Ramesh M Ther Adv Vaccines Immunother; 2019; 7():2515135519889000. PubMed ID: 31799496 [TBL] [Abstract][Full Text] [Related]
11. [Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010]. Zhang LP; Yu F; Jin BF; Wang Y; Xu HL; DU Y Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):859-64. PubMed ID: 23302620 [TBL] [Abstract][Full Text] [Related]
12. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India. Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922 [TBL] [Abstract][Full Text] [Related]
13. Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China. Wang C; Huang N; Lu QB; Black S; Liang X; Cui F Front Immunol; 2022; 13():956473. PubMed ID: 36248783 [TBL] [Abstract][Full Text] [Related]
15. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Menzies R; Mahajan D; Gold MS; Roomiani I; McIntyre P; Lawrence G Commun Dis Intell Q Rep; 2009 Dec; 33(4):365-81. PubMed ID: 20301966 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial. Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357 [TBL] [Abstract][Full Text] [Related]
17. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study. Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501 [TBL] [Abstract][Full Text] [Related]
18. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800 [No Abstract] [Full Text] [Related]
19. Factors associated with intention for revaccination among patients with adverse events following immunization. Muñoz CE; Pham-Huy A; Pernica JM; Boucher FD; De Serres G; Vaudry W; Constantinescu C; Sadarangani M; Bettinger JA; Tapiéro B; Morris SK; McConnell A; Noya F; Halperin SA; Top KA; Vaccine; 2023 Oct; 41(42):6239-6247. PubMed ID: 37666696 [TBL] [Abstract][Full Text] [Related]
20. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]